Skip to content

Aspira Women's Health

6 viewers · 30d

Total raised

$5.8M

+$1.5M this year

3 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $1.5M
ROUNDS
3
INVESTORS
27
FOUNDED
N/A
HQ
Austin, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Aspira Women's Health Inc. is a leading bio-analytical women's health company dedicated to the development of innovative diagnostic tools specifically for gynecologic diseases. With a strong focus on enhancing early detection and risk assessment, particularly for ovarian cancer, Aspira aims to address significant challenges in women's health diagnostics.

What sets it apart

What sets Aspira apart is its commitment to improving early detection rates for gynecologic diseases through a combined portfolio of proprietary blood tests and its own CLIA-certified laboratory, enabling reliable and swift results.

Funding history

3 rounds
Equity+2Jun 5, 2026
Form D
+$1.5M$5.8M total
Equity+2Sep 16, 2025
Form D
+$3.0M$4.3M total
Equity+2Mar 5, 2025
Form D
+$1.4M$1.4M total

Products

1 tracked

OvaSuite

Diagnostic Blood Tests

OvaSuite is a comprehensive suite of blood tests designed to aid in the assessment of ovarian cancer risk. It includes specific tests tailored to monitor and evaluate the presence of malignancy in adnexal masses.

  • OvaWatch: Monitors adnexal masses assessed as indeterminate or benign
  • Ova1Plus: Evaluates malignancy risk prior to surgery by combining the Ova1 and Overa tests